Navigation Links
Clinical Force Announces that Stiris Research has Selected the Clinical Force CTMS to Manage Clinical Trials
Date:10/15/2009

Clinical Force announces that Stiris Research has selected the Clinical Force CTMS to manage clinical trials. Stiris Research successfully implemented the Clinical Force CTMS in less than 4 weeks. With Clinical Force, Stiris Research anticipates significant study cost efficiencies that it can pass on to its pharmaceutical and biotech clients.

Raleigh, NC, October 16, 2009 -- Clinical Force announces that Stiris Research has selected the Clinical Force CTMS to manage clinical trials.

Stiris Research boasts best in class competencies in Project Management and Monitoring, providing partners and sponsors with dedicated expert teams and flexible SOPs . The next step in their growth model is to automate the clinical trial process by implementing a CTMS. Stiris Research successfully implemented the Clinical Force CTMS in less than 4 weeks. With Clinical Force, Stiris Research anticipates significant study cost efficiencies that it can pass on to its pharmaceutical and biotech clients.

Stiris Research believes the CTMS will further enhance Sponsors' clinical trial experience by providing:

 
  • Real Time access to study information - enabling instant quality checks
  • Customized study reporting - improving reporting quality
  • Investigator payment tracking - reducing administrative time
  • Regulatory document tracking and filing - providing 24/7 access to the trial master file
  • Automatic monitoring report and follow-up letter generation - saving time and cost

Stiris' President Shantal Feltham states it was Clinical Force's innovative implementation approach that led to the CTMS choice. "Stiris is an organization based on a team approach, commitment to service, and innovative problem solving for our clients. Clinical Force brought the same attributes to the CTMS implementation and proved to be the best fit for us and our clients. As Stiris grows, we look forward to offering our clients this expanded service while maintaining cost efficiencies."

Keep up to date on the Stiris Research CTMS project through this webpage. Stiris CTMS Project Status

About Clinical Force

Clinical Force delivers a best in class Clinical Trial Management System (CTMS) to Clinical Research Organizations (CROs) and Sponsors in North and South America, Europe and Africa. Clinical Force customers are successfully using the CTMS to improve their clinical trial execution, saving time and money. As the industry's first SaaS CTMS provider, Clinical Force has the most advanced SaaS solution and the most experience implementing and supporting the SaaS model. The SaaS model benefits Clinical Force customers with rapid and simple installation and a remarkably affordable total cost of ownership. Clinical Force is a rapidly growing, privately held company with strong life science pedigree. To stay close to our customers, Clinical Force has offices in the US and Europe. www.clinicalforce.com

About Stiris Research

Stiris Research is an elite CRO specializing in providing unparalleled Project Management and Monitoring expertise for Phase I-IV clinical trials. Stiris provides functional service or full service clinical trial support for pharmaceutical, biotech, and device companies. We work with our clients to provide customized solutions based on individual needs and resource requirements. Stiris is a certified Woman Owned Business Enterprise through WEConnect Canada, and has been recognized as one of Canada's top Women Entrepreneurial companies. Stiris has also been recognized as an Emerging Growth Company by Profit Magazine . www.stirisresearch.com

###

Read the full story at http://www.prweb.com/releases/CTMS/CROStirisClinicalForce/prweb3047214.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  Renova™ Therapeutics, a biotechnology ... failure and type 2 diabetes, announced that it ... adeno-associated virus (AAV) vector developed in the laboratory ... at Stanford University. The company plans to use ... therapy product pipeline. "Early research ...
(Date:12/8/2016)... Oxford Gene Technology (OGT), ... panel range with the launch of the SureSeq myPanel™ NGS ... variants in familial hypercholesterolemia (FH). The panel delivers single nucleotide ... single small panel and allows customisation by ,mix and match, ... for LDLR , P C SK9 ...
(Date:12/8/2016)... ... December 08, 2016 , ... This CAST literature review and report looks at ... focus on the economic effects in countries that are major global commodity exporters and ... the resultant risk of low level presence (LLP) puts large volumes of trade worth ...
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
Breaking Biology Technology:
(Date:12/5/2016)... , Dec. 5, 2016  The Office ... today published "Can CT Scans Enhance or Replace ... the potential of supporting or replacing forensic autopsies ... CT scan. In response to recommendations ... is exploring using CT scans as a potential ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
Breaking Biology News(10 mins):